<DOC>
	<DOCNO>NCT01529086</DOCNO>
	<brief_summary>The REDUCE trial conduct determine whether dutasteride reduces risk incident prostate cancer , detect biopsy , among men increase risk disease . Dutasteride compare placebo 4 year period . Results show relative risk reduction 22.8 % ( 95 % CI : 15.2 29.8 ) prostate cancer . For REDUCE , biopsy define `` protocol biopsy '' perform certain timeframes , `` cause '' outside predetermine timeframes . The investigator propose post hoc analysis would allow include biopsy really justified clinical indication , exclude `` cause '' analysis base occur either 2 4 year timeframes . Thus investigator propose analysis REDUCE group every yearly timeframe : Group 1 -- dutasteride group biopsied `` cause '' use several definition : biopsy patient receive dutasteride whose PSA rise nadir define protocol , PSA rise &gt; 0.2 ng/ml new abnormal DRE free PSA &lt; 12 % . The investigator define would reasonably instigate biopsy clinician patient scenario non-study setting . Group 2 -- placebo group biopsied `` cause '' use several definition , regardless timeframe report year study aggregate , aggregate number primary outcome . Thus investigator would request result biopsy patient receive placebo To establish difference biopsy positive rate group per definition list , determine dutasteride decrease likelihood `` cause '' biopsy compare `` cause '' biopsy , difference cancer detection risk rate depend cause vs. cause group compare placebo .</brief_summary>
	<brief_title>For Cause Prostate Biopsy REDUCE Population Trial</brief_title>
	<detailed_description>Purpose : Determining likelihood prostate cancer detection men take dutasteride biopsy perform 'for cause ' . Population : The population interest REDUCE Biopsied population , , subject Efficacy population least one post-baseline biopsy review Central Pathology Laboratory . Analyses : Initial interest focus data Year 1-2 time period , avoid potential effect cancer diagnose Year 2 scheduled biopsy assessment utilized `` cause '' definition . Only PSA data Years 1-2 baseline utilized computation various PSA metric , Central Pathology result Years 1-2 utilized establish post-baseline diagnosis . PSA value within 42 day date biopsy exclude analysis , avoid potential effect biopsy PSA value . For 2 group subject , follow summarize : number subject meet correspond criterion , number % subject diagnosed prostate cancer , number % subject diagnose Gleason 7-10 , number % subject diagnose either prostate cancer , HGPIN ASAP . Summaries number subject meet specific criterion group 1 ( e ) Group 2 ( h ) provide . In addition , summary investigate effect baseline variable ( age , family history prostate cancer , prostate volume , percent free PSA , number core entry biopsy ) occurrence prostate cancer diagnose Gleason 7-10 diagnosis may develop .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Group 1—subjects dutasteride treatment group meet follow set criterion : A rise PSA nadir time postnadir PSA change baseline &gt; 0.2 ng/ml time postbaseline Abnormal DRE time postbaseline Free PSA &lt; 12 % time postbaseline At least one 4 criterion . Group 2—subjects placebo treatment group meet follow set criterion : Change baseline PSA 0.0 0.35 ( ie , 0.0 ≤ change baseline PSA &lt; 0.35 ) time postbaseline . Note REDUCE PSA record near 0.1 . Abnormal DRE time postbaseline Change baseline PSA ≥ 0.35 time postbaseline Change baseline PSA ≥ 0.75 time postbaseline PSA ≥ 2.5 time postbaseline PSA ≥ 4.0 time postbaseline Percent Free PSA &lt; 12 % time postbaseline At least one 7 criterion .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>dutasteride</keyword>
	<keyword>cause prostate biopsy</keyword>
</DOC>